It revealed that of the 18,010 women in that cohort who were first prescribed GLP-1 medications during that time, only 21% reported using contraception, and 2.2% of women became pregnant within six months of starting GLP-1 treatment
Some readers may be familiar with the amino acid carnitine, which carries fatty acids into the mitochondria (the cellular furnaces), where they are oxidised for energy
Even among patients with diabetes, where the clinical case for continued treatment was strongest, 46.5 percent stopped within 12 months
Children aged 12 and older with a high BMI matching these adult criteria may be considered as well
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head